

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Etienne-Emile BAULIEU et al. )  
)  
Application No.: 10/542,495 )  
) Group Art Unit: Not Yet Assigned  
Filed: July 15, 2005 )  
) Examiner: Not Yet Assigned  
National Stage of International Application No. )  
PCT/FR2004/000086 under 35 U.S.C. 371 )  
)  
For: USE OF 3-METHOXY-PREGNENOLONE IN )  
THE PRODUCTION OF A MEDICAMENT FOR )  
TREATING NEURODEGENERATIVE )  
DISEASES )

**MAIL STOP - PCT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08. A copy of each listed document is attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: March 5, 2006

By: 

Ernest F. Chapman  
Reg. No. 25,961

Enclosures  
EFC/FPD/blc

<b>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/542,495
				Filing Date	July 15, 2005
				First Named Inventor	Etienne-Emile BAULIEU
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	03715.0148

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		KOLB et al., Nerve Growth Factor Treatment Prevents Dendritic Atrophy and Promotes Recovery of Function After Cortical Injury", Neuroscience, Vol. 76, No. 4, pp. 1139-1151, (1996).	
		ZHANG et al., "Cytoskeletal Disruption Following Contusion Injury to the Rat Spinal Cord", Journal of Neuropathology and Experimental Neurology, Vol. 59, No. 4, pp. 287-296, (2000).	
		SCHUMACHER et al., "Pretreatment with Calpain Inhibitor CPE-4143 Inhibits Calpain I Activation and Cytoskeletal Degradation, Improves Neurological Function, and Enhances Axonal Survival After Traumatic Spinal Cord Injury", Journal of Neurochemistry, Vol. 74, No. 4, pp. 1646-1655, (2000).	
		SPRINGER et al., "Rapid Calpain I Activation and Cytoskeletal Protein Degradation Following Traumatic Spinal Cord Injury: Attenuation with Riluzole Pretreatment", Journal of Neurochemistry, Vol. 69, No. 4, pp. 1592-1600, (1997).	
		MATUS, "MAP2", Microtubules, pp. 155-166, (1994).	
		SÁNCHEZ et al., "Phosphorylation of Microtubule-Associated Protein 2 (MAP2) and its Relevance for the Regulation of the Neuronal Cytoskeleton Function", Progress in Neurobiology, Vol. 61, pp. 133-168, (2000).	
		CACERES, et al., "Suppression of MAP2 in Cultured Cerebellar Macroneurons Inhibits Minor Neurite Formation", Neuron, Vol. 9, pp. 607-618, (1992).	
		HARADA et al., "MAP2 is Required for Dendrite Elongation, PKA Anchoring in Dendrites, and Proper PKA Signal Transduction", The Journal of Cell Biology, Vol. 158, No. 3, pp. 541-549, (2002).	
		REYNA-NEYRA et al., "Estradiol and Progesterone Modify Microtubule Associated Protein 2 Content in the Rat Hippocampus", Brain Research Bulletin, Vol. 58, No. 6, pp. 607-612, (2002).	
		NAKATOMI et al., "Regeneration of Hippocampal Pyramidal Neurons after Ischemic Brain Injury by Recruitment of Endogenous Neural Progenitors", Cell, Vol. 110, pp. 429-441, (2002).	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/542,495
				Filing Date	July 15, 2005
				First Named Inventor	Etienne-Emile BAULIEU
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	03715.0148

		GARCÍA-ESTRADA et al., "Dehydroepiandrosterone, Pregnenolone and Sex Steroids Down-Regulate Reactive Astroglia in the Male Rat Brain after a Penetrating Brain Injury", Int. J. Devl. Neuroscience, Vol. 17, No. 2, pp. 145-150, (1999).	
		LEGRAND et al., "Pregnenolone Reverses the Age-Dependent Accumulation of Glial Fibrillary Acidic Protein within Astrocytes of Specific Regions of the Rat Brain", Brain Research, Vol. 802, pp. 125-132, (1998).	
		GUTH et al., "Key Role for Pregnenolone in Combination Therapy that Promotes Recovery after Spinal Cord Injury", Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 12308-12311, (1994).	
		GURSOY et al., "Pregnenolone Protects Mouse Hippocampal (HT-22) Cells Against Glutamate and Amyloid Beta Protein Toxicity", Neurochemical Research, Vol. 26, No. 1, pp. 15-21, (2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.